Q3 2014 13F Holders as of 30 Sep 2014
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
444,806,861
-
Total 13F shares
-
4,110,787
-
Share change
-
+2,850,731
-
Total reported value
-
$4,188,897
-
Price per share
-
$1.02
-
Number of holders
-
27
-
Value change
-
+$2,916,157
-
Number of buys
-
9
-
Number of sells
-
10
Institutional Holders of PROVECTUS BIOPHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (PVCT) as of Q3 2014
As of 30 Sep 2014,
PROVECTUS BIOPHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (PVCT) was held by
27 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,110,787 shares.
The largest 10 holders included
VANGUARD GROUP INC, GOLDMAN SACHS GROUP INC, UBS AG, Knoll Capital Management, LP, Commonwealth Equity Services, Inc, Creative Planning, LPL Financial LLC, AMERICAN INTERNATIONAL GROUP INC, HUDSON CANYON INVESTMENT COUNSELORS LLC, and Private Advisor Group, LLC.
This page lists
27
institutional shareholders reporting positions in this security
for the Q3 2014 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.